[The Correlation of Serum CMTM6 and CCN1 Expression with Clinical Efficacy and Prognosis of Patients with Acute Leukemia].

Abstract

Objective: To determine the serum levels of CMTM6 mRNA and CCN1 in patients with acute leukemia (AL), and to analyze their relationship with the clinical efficacy and prognosis of the patients.

Methods: 103 AL patients admitted to our hospital from February 2015 to January 2019 were included as the study subjects. Additionally, 100 healthy subjects who underwent physical examinations during the same period were included as the control group. qRT-PCR method was applied to detect the serum CMTM6 mRNA level of the study subjects, the serum CCN1 level was measured by ELISA. The levels of serum CMTM6 mRNA and CCN1 between the control group and AL patients, as well as between patients at initial diagnosis and after one course of chemotherapy were compared, the correlation of CMTM6 mRNA and CCN1 levels at initial diagnosis with clinicopathological features and short-term efficacy in AL patients was analyzed. The correlation of the CMTM6 mRNA and CCN1 expression levels with prognosis of the patients was analyzed by Kaplan-Meier curves.

Results: Compared with the control group, the serum CMTM6 mRNA level in AL patients was significantly increased (P < 0.05), while the serum CCN1 level was significantly decreased (P < 0.05). There were no statistically significant differences in serum CMTM6 mRNA and CCN1 levels between patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (P >0.05). Compared with those at the initial diagnosis, both the serum CMTM6 mRNA and CNN1 expression levels in AL patients were significantly altered after one course of chemotherapy, with CMTM6 mRNA significantly decreased (P < 0.05) and CCN1 significantly increased (P < 0.05). The 3-year recurrence-free survival (RFS) rate was lower in the CMTM6 high expression group and the CCN1 low expression group, compared with the CMTM6 low expression group and CCN1 high expression group, respectively (P < 0.05).

Conclusion: Serum CMTM6 is highly expressed and CCN1 is lowly expressed in AL patients. The expression levels of serum CMTM6 and CCN1 are associated with the 3-year prognosis of the patients.